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Background: We recently evaluated four laboratory assays, vascular endothelial growth factor D 
(VEGF-D), E-cadherin, lymphatic vessel density (LVD) measured by podoplanin, and intra-lym- 
phatic tumor emboli (ILTE), which showed notable differences between inflammatory breast can-
cer (IBC) and non-inflammatory locally advanced breast cancer (LABC). In this study we investi-
gated the potential of the three most quantitatively measured markers, E-cadherin, LVD and 
VEGF-D, to predict survival in the IBC patients. Materials and Methods: This study involved the 100 
cases identified in the Inflammatory Breast Cancer Registry (IBCR) whose tumors were previously 
evaluated for the four assays noted above. Living patients were recontacted and survival data 
were available for up to 17 years. Overall survival (OS) was analyzed through the Kaplan-Meier 
method stratified by E-cadherin, LVD, VEGF-D, and response to chemotherapy. The differences in 
OS curves were compared using the log-rank test. Results: The median OS for patients with high 
LVD was 6.63 years (95% CI: 4.06 to 10.14), compared to median at 10 years not reached in those 
with low LVD (p = 0.03). There was a trend towards a longer median OS in patients with high 
E-cadherin (10.14, 95% CI: 6.63 to 11.67), compared with those with low E-cadherin (6.26, 95% CI: 








significantly predicts better survival. High E-cadherin expression, as with non-IBC breast cancer 
and several other malignancies, tends to be associated with a better prognosis. 
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Inflammatory breast cancer (IBC) is an unusual form of breast cancer marked by aggressiveness and biological 
behavior with a tendency to disseminate micrometastases from the outset rather than develop in a more con-
trolled stepwise progression as seen in most carcinomas. Considered by some oncologists as a subgroup of lo-
cally advanced breast cancer (LABC) since they appear clinically similar, this appears to be misleading because 
LABC is usually the result of delay in diagnosis. LABC may not have the same extent of metastatic disease, has 
a better prognosis than IBC, and is declining in incidence while IBC appears to be increasing in incidence [1]. 
An important clinical feature of IBC is the marked response to chemotherapy, which may contribute to survival; 
the initial response to chemotherapy is an important predictor of long term survival [2]. Previous analysis of data 
from the IBC registry indicates that estrogen receptors and HER2-neu confer an advantage to the patient by al-
lowing the long term use of therapy aimed at these particular receptors [2]. We recently evaluated several poten-
tial prognostic markers in a study assessing laboratory markers differentiating IBC from LABC, VEGF-D, 
E-cadherin, lymphatic vessel density (LVD) measured by podoplanin, and intra-lymphatic tumor emboli (ILTE) 
[3]. With the advantage of a long follow-up of the IBC patients in our IBC registry, we investigated the prog-
nostic value of the three quantitative assays in determining long-term survival in IBC. 
2. Materials and Methods 
2.1. Patients and Tumor Samples 
The details of the patient selection and laboratory assays utilized in this study have been reported previously [3]. 
Dates of patient observation ranged from July 25, 1991 (date of diagnosis for first patient) to September 21, 
2011 (last date of follow-up for the long-term survivors). Briefly, 100 IBC patients were classified into two 
groups. A case was considered classic IBC if there was documentation of classical history and physical findings 
of erythema and peau d’orange involving the majority of the breast or histopathologic confirmation of dermal 
lymphatic invasion (DLI) that met the criteria for IBC diagnosis by the American Joint Committee on Cancer 
(AJCC) and/or the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. A 
group of atypical IBC cases with the clinical signs of IBC, also appearing acutely but differing from classic IBC 
because of involvement of less than half the breast [4], were compared with the classic IBC cases to investigate 
the validity of current case definitions. Approximately half of the samples examined were from pre-treatment 
biopsies and the other half were from post-chemotherapy mastectomies. Chemotherapy in all cases included at 
least three drugs, adriamycin in all cases and usually cyclophosphamide and a taxane. The doses varied accord-
ing to individual physician preferences and patient responses. 
2.2. Immunohistochemical (IHC) Evaluation of Tumor Samples 
IHC staining of ER, podoplanin, E-cadherin and VEGF-D was performed on the IBC and non-IBC paraffin- 
embedded tumor tissues using previously described methods [5] [6]. The antibodies used for ER, podoplanin 
and E-cadherin included mouse monoclonal anti-ER (clone 1D5, Dako Corporation), mouse monoclonal anti- 
podoplanin (clone AB03, AngioBio Co.), and mouse monoclonal anti-E-cadherin (clone 36B5, Chemicon Inter-
national Inc.). Immunochemistry for VEGF-D used anti-VEGF-D antibody (rabbit polyclonal SC-25784) from 
Santa Cruz Biotechnology at 1:100 after antigen retrieval at pH (in a pressure cooker for 20 minutes. The anti-
gen-antibody reaction was detected by Dako Envision + detection sysrem and DAB. 
2.3. Determination of Response to Chemotherapy 
Clinical response to chemotherapy was categorized as complete, partial, or none. The response to chemotherapy 




was first categorized in the initial patient telephone interview and confirmed by review of the patient records 
(both by PHL) after the completion of chemotherapy. Patient response was defined as complete if she reported 
rapid resolution to normal breast size and appearance, usually before the second round of chemotherapy. Partial 
response was defined as a gradual but definite improvement over several courses of chemotherapy, with clinical 
manifestations minimal or absent at the time of mastectomy. No discordances were seen between the patient’s 
and her clinician’s reports. 
2.4. Statistical Analysis 
E-cadherin expression was quantitatively analyzed using an Automated Cellular Imaging System (ACIS) as pre-
viously described [6] [7]. Six areas of tumors were measured with a 40× scoring tool in ACIS. Staining Index 
(SI) was determined by staining intensity × % staining per 100. To validate the automated image analysis of 
E-cadherin, every 5th slide was read blindly by a pathologist and compared to the ACIS score. The scores were 
shown to be correlated, with a correlation coefficient of 0.501. 
Patients were categorized as having elevated or low E-cadherin levels with a level of 2.0 being the dividing 
line based on the distribution of the data, this value distinguishing between the two groups (Figure 1(a)). As 
shown in the histogram of LVD (Figure 1(b)), one-third of patients had a LVD value of zero. Patients were ca-
tegorized as high LVD if they had levels greater than zero and low if they were equal to zero. Patients were ca-
tegorized as having low or high VEGF-D levels based on the distribution of VEGF-D seen in the histogram 
(Figure 1(c)) with 145 chosen as the value to distinguish between the two groups. 
Survival curves stratified by E-cadherin, LVD, and VEGF-D were estimated using the Kaplan-Meier method 
and compared for statistically significant differences using the log-rank test. Overall survival curves using the 
Kaplan-Meier method were estimated using stratification of response to chemotherapy and levels of E-cadherin 
and LVD. Since we had previously shown that response to chemotherapy was an important predictor of survival 
[2], E-cadherin and LVD were evaluated for predicting response to chemotherapy using a chi-square test and lo-
gistic regression. All statistical tests were 2-sided, and the level of significance was set at 0.05. All statistical 
analyses were performed using SAS software, Version 9.2 (SAS Institute, Cary, NC). 
3. Results 
For all patients with available E-cadherin data (n = 99), the median survival time was 8.39 years (95% CI: 6.20 
to 11.43). Approximately 50% of the IBC patients had a low E-cadherin level (<2) comparable to levels of ex-
pression seen in non-IBC breast cancer [3] [8] (Figure 1(a)). The median survival time for patients with high 
E-cadherin levels (n = 52) was 10.14 years (95% CI: 6.63 to 11.67). The median survival time for patients with 
low E-cadherin levels (n = 47) was 6.26 (95% CI was not calculable). A Kaplan-Meier survival curve for E-cad- 
herin was not significant (p = 0.24), though there was a distinct separation between high and low E-cadherin le-
vels around year 10, in which the remaining sample size was greatly decreased (Figure 2(a)). A multiple com-
parison test of E-cadherin and response to treatment was statistically significant (p = 0.016), so higher E-cadhe- 
rin and better response to chemotherapy was associated with increased survival probability (Figure 2(b)). Of the 
few patients who had no response to chemotherapy, six patients had high E-cadherin levels and two patients had 
low E-cadherin levels. 
LVD also appeared to show at least two populations of IBC patients (Figure 1(b)) with the highest number of 
patients being in the group with no detectable LVD greater than zero (low). The median survival time for pa-
tients with a low LVD (n = 33) appeared to be significantly greater than those with observable lymphatic vascu-
lar involvement (n = 66), the median survival for the latter group being 6.63 years (95% CI: 4.06 to 10.14) whe-
reas the group with median survival of the LVD zero group was not reached at 10 years. The Kaplan-Meier sur-
vival curve shows a statistically significant (p = 0.0288) separation between these two LVD groups, where low 
LVD is associated with better survival (Figure 3(a)). A multiple comparison test of LVD and response to che-
motherapy was statistically significant (p = 0.017), so low LVD and better response to chemotherapy was asso-
ciated with increased survival probability. A multiple comparison of E-cadherin and LVD was not statistically 
significantly associated with overall survival (p = 0.12) (Figure 3(b)). There was a small sample of patients in 
some of the cells for analysis, specifically the none category for response to chemotherapy, with low LVD hav-
ing three patients and high LVD having five patients. 
For VEGF-D, no particular distribution pattern was observed (Figure 1(c)). There was not a significant  





(a)                                     (b)                                   (c) 
Figure 1. Histograms showing the distributions of (a) E-cadherin; (b) LVD; and (c) VEGF-D.                                      
 
 
(a)                                                   (b) 
Figure 2. Kaplan-Meier survival curves stratified by (a) E-cadherin; and (b) E-cadherin and response to chemotherapy.                  
 
 
(a)                                                   (b) 
Figure 3. Kaplan-Meier survival curves stratified by (a) LVD; and (b) LVD and response to chemotherapy.                         
 
association (p = 0.39) between VEGF-D and overall survival. We also saw no effect of the presence or absence 
of estrogen receptors on the prognostic value of LVD or E-cadherin. 
E-cadherin (p = 0.32) and LVD (p = 0.54) did not predict response to chemotherapy. 
4. Discussion 
Inflammatory breast cancer (IBC) is a phenotypically distinct and unique form of breast cancer [8] [9]. IBC is 
arguably the most aggressive form of breast cancer and carries a guarded prognosis with 5- and 10-year disease- 
free survival rates approaching 45% and 20%, respectively. The morbidity of this disease is presumably due to 
the presence of tumor emboli in the dermal lymphatic vessels where they rapidly disseminate throughout the 
body [8]. Thus, the poor prognosis of IBC is due to extensive metastases to distant sites, particularly visceral 
organs [10]. IBC is clinically distinguished by rapid onset of primary skin changes, typically occurring within 
twelve weeks and progression to stage IIIb/IV disease within 6 months [8] [9] [11]. The clinical manifestation of 




IBC often resembles mastitis, presenting without a palpable mass, with primary IBC tumors presenting as dif-
fuse sheets or cords of cells, which rapidly invade the dermal lymphatic vessels of the skin overlying the breast 
[8] [9] [11]. 
We evaluated three quantitative assays (LVD, E-cadherin and VEGF-D) found to differ between IBC and 
LABC in a previous study (3). Low LVD significantly predicted better survival, an expected finding as LVD is 
associated with IBC compared to non-inflammatory breast cancer and is associated with tumor aggressiveness 
(3). 
E-cadherin, which has a molecular signature that is unique from other forms of breast cancer [12], also was 
associated with prognosis, high levels of expression correlating with a better prognosis. The cell adhesion mo-
lecule, E-cadherin, is highly expressed in a number of IBC cell lines and patient samples [13]-[16]. Convention-
ally, E-cadherin is thought of as a tumor suppressor and its loss contributes to tumor progression and metastasis 
[17]-[19]. Thus, the high level of E-cadherin expression in metastatic IBC is counter-intuitive. 
It is suggested that IBC metastasizes via emboli spreading throughout the body by a process termed “passive 
metastasis” [20]. This hypothesis comes from a study where using palpation the intratumoral pressure of an IBC 
xenograft in a mouse model was increased, leading to detectable circulating tumor cells and increased pulmo-
nary metastasis. However, studies with other types of tumors have demonstrated that palpation leads to in-
creased shedding of tumor cells in the circulation [21]. Also, given the anatomy of the dermal lymphatics and 
the oscillatory flow of lymphatic fluid, it is unlikely that the patterns of IBC metastasis can be explained by em-
boli passively drifting through the lymphatics [22]-[24]. Data using an in vitro model of IBC emboli suggests 
that IBC cells continue to express E-cadherin while invading in a collective manner with motile cells being at-
tached to one another [25]. Comparative studies of MARY-X, a human xenograft model of IBC with non-IBC 
xenografts indicated 10-20-fold overexpression of E-cadherin and MUC1, findings that were reflected in actual 
cases of human inflammatory breast cancer, and a 360˚ circumferential distribution around the cancer cell mem-
brane accounting for the formation of the lymphovascular embolus [14] [16] [26]. The lack of sialyl-Lewis X/A 
on MUC1 on MARY-X is suggested to account for the lack of tumor-endothelial cell attachment both in vitro 
and in vivo, which in turn facilitates metastasis [27]. Thus, it is speculated that a combination of high E-cadherin 
and MUC1 on IBC cells facilitates metastasis; however this model does not explain the rapid spread of IBC, nor 
does it explain the patterns of IBC dissemination counter-current to lymphatic flow. 
Several studies in multiple tumor types suggest that E-cadherin expression correlates with disease progression 
and patient survival. A comparison of E-cadherin expression with classical histopathological features in bladder 
tumor specimens revealed that abnormal (negative or heterogenous) expression detected by immunohistochemi-
stry correlated with both stage and grade and with tumor shape and size. Analysis of recurrence, progression and 
survival over a mean period of 36 months after surgery for bladder cancer showed that decreased E-cadherin 
immunoreactivity correlated strongly with poor outcome [28]. In another study, decreased E-cadherin expres-
sion was found to correlate with decreased myometrial invasion and was predictive for endometrial cancer mor-
tality, disease progression, and extrapelvic recurrence, independent of known prognostic factors such as stage, 
grade, and histological subtype. There was a statistically significant decrease in overall survival (OS) in patients 
having tumors with decreased E-cadherin expression [29]. 
In a study of reduced E-cadherin expression in stage IV Wilms’ tumor, heterozygous mutations were identi-
fied in the adhesion domain and intracellular portion of the E-cadherin. The study showed a significant associa-
tion between E-cadherin expression and stage of disease with low expression corresponding to a 16.25 times in-
creased risk for the presence of stage IV disease [30]. Investigation into the various aspects of E-cadherin bio-
logical activity, particularly in prostate cancer progression, revealed that the highly invasive, fibroblastic-like 
subpopulation of DU145 cells expressed less than 0.1-fold of E-cadherin protein when compared to the poorly 
invasive parental DU145 cells. An 80 kDa E-cadherin fragment was detected, which on functional analyses re-
vealed a stimulatory effect on the migratory and invasive capability of E-cadherin-positive cells [31]. In contrast 
to high E-cadherin expression in normal epithelia, ovarian surface epithelium exhibits some mesenchymal cha-
racteristics and contains little or no E-cadherin [32]. 
Prognostic indicators are important in cancer treatment as they may help group patients into subgroups re-
quiring different types of treatment. Of four markers we evaluated to distinguish IBC from LABC [3], we inves-
tigated the prognostic value of the three most quantitative assays measuring LVD, VEGF-D and E-cadherin. In 
the present study we demonstrate that there are two identifiable populations of IBC patients that vary in their 
E-cadherin expression. The patients with tumor emboli with lower E-cadherin expression have a worse progno-




sis than those with high E-cadherin expression. Interestingly, melanoma also undergoes lymphovascular inva-
sion and there are reports of “inflammatory melanoma”; invasion of the dermal lymphatics by melanoma cells 
with a clinical presentation very similar to IBC [33]. Using the in vitro model of IBC emboli formation also stu-
died a number of metastatic melanoma clones and demonstrated that although they formed tight emboli, did not 
express E-cadherin [25]. 
In a large study of invasive breast cancer (374 cases) of all stages, it was found that lymphatic microvessel 
density (LMVD) correlated with lymphatic vascular invasion (LVI) [34]. LMVD was associated more often 
with a risk of developing lymph node metastatses. However, in this study there was a significant decrease in pa-
tient’s survival whose tumors had LVI (p = 0.0001) but not significant in those with LMVD (p = 0.78). Two 
other studies found that LMVD was significantly associated with lymph node metastatses and shorter survival in 
largely early stage breast cancer [35] [36]. In our study LVD low was associated with a significantly better sur-
vival, which is consistent with the two previously mentioned studies. 
We hypothesize the possibility of phenotypic transition phases in the life of an IBC tumor cell or embolus 
where variable expression of different surface receptors either induce a “latent state”, e.g. through a decrease in 
sialyl-Lewis X/A, thus inhibiting cell-matrix interactions and hence invasiveness [20], or an “active state”. To 
define the active state we refer to a study [37], which showed that IBC SUM149 cells seeded in a media condi-
tioned by human monocytes U937 cells, displayed motile phenotype, formed branched like structures associated 
with overexpression of fibronectin, whereas no alteration in the expression of E-cadherin was detected. IL-8 and 
MCP-1 were the major highly secreted cytokines by U937 cells [37], thus the role of tumor microenvironment in 
defining IBC features. Discussions within the IBC research community have focused on the thought that IBC 
cells are extremely plastic with regards to the epithelial to mesenchymal transition (EMT) [38]. It is suggested 
that IBC cells remain in an epithelial state but are primed to undergo EMT through co-expression of both epi-
thelial and mesenchymal markers and then quickly revert back to an epithelial state. Our data suggests that there 
may be a population of IBC cells with low or no E-cadherin expression that are able to readily undergo EMT; 
however, this remains to be tested. 
5. Conclusion 
In summary, our data from the IBC registry indicate that the initial response to chemotherapy is the most impor-
tant predictor of survival in IBC [2] but three other independent predictors of better prognosis are low LVD, 
high E-cadherin level and decreased diagnostic delay. One possible limitation to our laboratory data is the po-
tential effect of chemotherapy on the various assays, but in our earlier study comparing E-cadherin, LVD, 
VEGF-D and ILTE in IBC vs. LABC [3] no difference was found between the patients whose tissues were pre- 
treatment biopsies compared to those whose samples were post-chemotherapy mastectomies. 
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